Combined mexiletine and flecainide for severe long QT syndrome type 3

Pediatr Int. 2023 Jan;65(1):e15517. doi: 10.1111/ped.15517.

Authors

Toshiyuki Shimizu¹, Shun Kawai¹, Aiko Kawada¹, Takuya Wakamiya¹, Yusuke Nakano¹, Shigeo Watanabe¹, Mari Iwamoto²

Affiliations

¹ Department of Pediatric Cardiology, Yokohama City University Hospital, Yokohama, Kanagawa, Japan.
² Department of Pediatrics, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan.

PMID: 36847291
DOI: 10.1111/ped.15517

No abstract available

MeSH terms

Anti-Arrhythmia Agents / therapeutic use
Cardiac Conduction System Disease
Electrocardiography
Flecainide / therapeutic use
Humans
Long QT Syndrome* / diagnosis
Long QT Syndrome* / drug therapy
Mexiletine* / therapeutic use

Substances

Mexiletine
Flecainide
Anti-Arrhythmia Agents

Supplementary concepts

Long QT syndrome type 3